This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer ... cells is a microenvironment of ...

Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications who had progressed on prior immune ...

The frequency of TI-CH and its effect on tumor evolution are unclear. We characterized CHIP and TI-CH in 421 patients with early-stage non–small-cell lung cancer (NSCLC) from the TRACERx study ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy in a cervical cancer model.Clinical ...

Tumor-infiltrating clonal hematopoiesis (TI-CH) increased the risk of disease recurrence or death among patients with early ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both ...

BNT327, a PD-L1/VEGF therapy, is still currently being manufactured in China, but BioNTech is working to establish a ...